Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Guaifenesin warning letter

This article was originally published in The Tan Sheet

Executive Summary

Carolina Pharmaceuticals' guaifenesin- and potassium guaiacolsulfonate-containing products are unapproved new drugs, FDA states in a March 12 warning letter citing Humibid L.A. and Humibid DM (which also contains dextromethorphan). The agency "is unaware of substantial scientific evidence" showing such a combination "is generally recognized by qualified experts as safe and effective," the letter states. The products also are considered new drugs because labeling describes them as offering sustained-release formulations, which must be approved, FDA states. The letter notes the products are reformulated versions of drugs previously marketed under the Humibid brand. The Cary, N.C. firm purchased rights to the brand name at the end of a grace period temporarily allowing continued Rx sale of single-ingredient extended-release guaifenesin products (1"The Tan Sheet" March 3, 2003, p. 4)...

You may also be interested in...



FDA Focus On Food Safety Regulations May Delay OTC And Supplement Rules

FDA will try to eke out rules on OTC drug reviews and supplement labels in 2012 with its hands full implementing the food safety act. In the latest regulatory agenda, FDA priorities include an NPRM on foreign supplier verification and regulations to accredit third-party auditors to inspect firms across the agency’s oversight.

FDA Focus On Food Safety Regulations May Delay OTC And Supplement Rules

FDA will try to eke out rules on OTC drug reviews and supplement labels in 2012 with its hands full implementing the food safety act. In the latest regulatory agenda, FDA priorities include an NPRM on foreign supplier verification and regulations to accredit third-party auditors to inspect firms across the agency’s oversight.

Rx Extended-Release Guaifenesin Must Exit Market By November, FDA Says

Single-ingredient, extended-release prescription guaifenesin products must be removed from the market by the end of November if they have not been approved by FDA, the agency states in Feb. 25 letters to 66 marketers and distributors of the drugs

Topics

UsernamePublicRestriction

Register

ID1132281

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel